相似文献
1
Ponatinib: Accelerated Disapproval.
Oncologist. 2015 Aug;20(8):847-8. doi: 10.1634/theoncologist.2015-0253. Epub 2015 Jul 14.
2
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia.
Br J Haematol. 2019 Oct;187(1):e15-e17. doi: 10.1111/bjh.16132. Epub 2019 Aug 1.
3
Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther. 2013 Sep 2;55(1424):71-2.
4
Success is built on failures: tackling the challenge of ponatinib failure.
Leuk Lymphoma. 2018 Jun;59(6):1279-1281. doi: 10.1080/10428194.2018.1427864. Epub 2018 Jan 31.
5
Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
Clin Adv Hematol Oncol. 2011 Dec;9(12):925-6.
6
Experience with ponatinib in paediatric patients with leukaemia.
Br J Haematol. 2020 Apr;189(2):363-368. doi: 10.1111/bjh.16338. Epub 2020 Jan 24.
7
Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun.
Protein Cell. 2019 Mar;10(3):161-177. doi: 10.1007/s13238-018-0533-8. Epub 2018 Apr 17.
8
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.
9
Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Drugs Today (Barc). 2013 Apr;49(4):261-9. doi: 10.1358/dot.2013.49.4.1950147.
10
The current status of ponatinib in the treatment of chronic myeloid leukemia.
Clin Adv Hematol Oncol. 2014 May;12(5):329-31.
引用本文的文献
1
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies.
Biomark Res. 2025 Apr 18;13(1):62. doi: 10.1186/s40364-025-00779-x.
2
Overcoming Secondary Mutations of Type II Kinase Inhibitors.
J Med Chem. 2024 Jun 27;67(12):9776-9788. doi: 10.1021/acs.jmedchem.3c01629. Epub 2024 Jun 5.
3
Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
Lab Chip. 2024 Feb 13;24(4):869-881. doi: 10.1039/d3lc00745f.
4
Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives.
Front Oncol. 2023 Nov 8;13:1244775. doi: 10.3389/fonc.2023.1244775. eCollection 2023.
5
Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist.
Cell Death Dis. 2023 Aug 24;14(8):555. doi: 10.1038/s41419-023-06065-8.
6
Improving drug discovery with a hybrid deep generative model using reinforcement learning trained on a Bayesian docking approximation.
J Comput Aided Mol Des. 2023 Nov;37(11):507-517. doi: 10.1007/s10822-023-00523-3. Epub 2023 Aug 8.
7
Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Signal Transduct Target Ther. 2023 May 11;8(1):198. doi: 10.1038/s41392-023-01460-1.
8
Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling.
Molecules. 2023 Jan 17;28(3):943. doi: 10.3390/molecules28030943.
9
Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation.
Circ Res. 2023 Feb 3;132(3):267-289. doi: 10.1161/CIRCRESAHA.122.321504. Epub 2023 Jan 10.
10
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
J Med Chem. 2022 Aug 25;65(16):10898-10919. doi: 10.1021/acs.jmedchem.1c01853. Epub 2022 Aug 9.
本文引用的文献
1
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.
Leuk Res. 2016 Sep;48:84-91. doi: 10.1016/j.leukres.2016.07.007. Epub 2016 Jul 22.
2
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.
3
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.
4
Accelerated approval of oncology products: the food and drug administration experience.
J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21.
5
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
Clin Cancer Res. 2008 Jul 15;14(14):4392-9. doi: 10.1158/1078-0432.CCR-08-0117.
Zotero 插件